Product Liability Lawyer Blog
Xarelto, Eliquis, Pradaxa, and the newly-marketed Savaysa are all members of a class of drugs known as New Oral Anticoagulants (NOACs). They are all advertised as a safer and easier to use alternative to Warfarin (Coumadin), which has been the long-standing drug prescribed to patients who suffer from an irregular heartbeat condition known as atrial fibrillation (Afib).
Afib patients require either a blood thinner like Warfarin or an oral anticoagulant like Xarelto to decrease the risk they will develop a serious clotting disorder. If patient develops clots deep within the veins of his or her legs, which is known as deep vein thrombosis (DVT), the clots can break loose and travel to the lungs, where they can puncture the tissue, causing a potentially deadly condition known as pulmonary embolism (PE). The clots can also block blood flow to the brain, which results in a stroke. Continue reading